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Summary.-In 181 consecutive patients with breast cancer, urinary hydroxyproline
excretion has been critically evaluated in conjunction with clinical, biochemical,
radiological and scintigraphic parameters. The urinary hydroxyproline/creatinine
ratio is a sensitive index of the presence of bone metastases.
Urinary hydroxyproline excretion is a reliable method of selecting those patients
whose elevated serum alkaline phosphatase is secondary to bone disease rather than
liver disease.
The estimation of hydroxyproline excretion furthermore gives information on the
activity of bone metastasis, and its response to treatment, which cannot be given by
radiological or scintigraphic methods.
It is doubtful whether urinary hydroxyproline estimation will help to detect bone
metastases before they are apparent on scintigrams. When the bone scan is doubt-
ful, as often occurs in older subjects, hydroxyproline excretion has been found to
be helpful in classifying the patient. When scintigraphy is not available, an elevation
of hydroxyproline excretion, together with an elevation of Ca/cr ratio or alkaline
phosphatase activity, may pre-date by several months the radiological demonstra-
tion of osseous metastases.
THE APPROPRIATE staging of patients
with carcinoma ofthe breast is of primary
importance to the rationalization of the
choice of subsequent treatment. The
skeleton is the most common site for
netastases from carcinoma of the breast.
In 85% of women dying from this parti-
cular disease, skeletal lesions were found
when a careful autopsy had been carried
out (Jaffe, 1958).
The radiological detection of skeletal
metastases is dependent on extensive
destruction of bone. There must be at
least a 30%0 reduction in calcium content
or destruction of the bony architecture
before lesions become apparent. In ver-
tebrae, lesions less than 1-5 cm in diameter
cannot be visualized (Galasko, 1969;
Bachman and Sproul, 1955). Many
workers, using differing radionuclides and
detectors,have claimedsuperiorityforscin-
tigraphy over radiography in the early
detection of bone metastases. Despite
the development of this technique
McCormick et al. (1975), using 87Sr in
scintigrams, report a significant number of
false positive (7%0) and false negative
scans (1400). Since radioisotopes ofstron-
tium, fluorine and technetium polyphos-
phateare concentrated at sites ofnew bone
formation, false negative scans are usually
seen in patients with pure osteolytic
lesions (Denardo, Jacobson and Raventos,
1972; Galasko and Doyle, 1972).
Hydroxyproline excretion is considered
to be a reflexion of bone collagen turnover
(Dull and Henneman, 1963; Prockop
and Sjoerdsma, 1961). Increased hydroxy-
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prolinuria has been found in patients
with bone metastases. Since elevation
in excretion seem to occur with
osteoblastic as well as osteolytic lesions
(Platt, Doolittle and Hartshorn, 1964;
Hosley et al., 1966), an examination of
urinary hydroxyproline excretion may
well be of value in detecting early bone
metastases and be useful for appropriate
staging ofpatients with breast cancer.
The present report is a prospective
study of hydroxyproline excretion in
breast cancer patients with and without
metastases. The purpose of the study is,
first, to delineate the usefulness of
hydroxyproline excretion as an index of
the presence and development of meta-
static bone disease and, second, to examine
the relationship of this aminoaciduria
to calcium excretion and serum alkaline
phosphatase levels.
MATERIALS AND METHODS
One hundred and eighty-one consecutive
patients with biopsy-proven carcinoma ofthe
breast, age range 32-85, who were admitted
for investigation over a one-year period,
were investigated. Each patient underwent
a careful clinical examination, a radiological
skeletal survey, a skeletal scan with 99techne-
tium polyphosphate and a biochemical
evaluation ofliver, kidney and bone function.
The biochemical evaluation of bone metabo-
lism consisted of serum calcium, phosphorus
andalkalinephosphataseactivityandmeasure-
ment of urinary calcium and total hydroxy-
proline levels.
Since there might be daily variations in
urinarycalciumandhydroxyproline excretion,
the mean value of 3 consecutive 24-h collec-
tions was used. All patients followed a
standardized diet with low calcium and gela-
tine content. Urinary hydroxyproline was
measured by the method of Haury (1972).
Calcium, phosphorus, creatinine and alka-
line phosphatase activity were measured by
standard technicon autoanalyser methods.
Calcium and hydroxyproline excretion are
expressed as absolute values and as an index
-calcium orhydroxyproline/creatinine x 100
and calcium or hydroxyproline/creatinine/m2
surface area x 100-in order to correct for
errors in the urine collections and body size
respectively. Urinary hydroxyproline levels
were not estimated on admission but stored
for estimation later, so clinical staging of the
patient was independent of these results.
Except for 2 patients, all the patients
were reviewed clinically, together with
repeated limited skeletal survey if indicated,
at frequent intervals up to 1 5-2 years. The
notes of the patients who died within this
interval were carefully analysed.
Classification
All patients were classified into 4 groups
according to the presence or absence of
metastases to bone or soft tissue, based on
clinical, radiological and scintigraphic evalua-
tion.
Group 1: No radiological or scintigraphic
abnormalities (Rx-Scan-).
Group 2: Definite radiological and scinti-
graphic lesions (Rx+Scan+).
Group 3: No radiological lesionbut adoubtful
scintigraphic lesion (Rx- Scan +).
Group 4: Soft tissue metastases only.
In the analysis of the results 10 patients
were eliminated: 2 because of lack of follow-
up, 8 because ofthe presence ofanother illness
which mightaffectthebiochemicalparameters
(hepatitis or cirrhosis (4), chronic bronchitis
with clubbing (1), hyperthyroidism (1),
rectum carcinoma (1), and fibrous dysplasia
(1)). Nine of these belonged to Group 1
and one to Group 3.
The patients who during the follow-up
period were found to have developed skeletal
(14) or soft tissue metastases (13) are listed
separately in their original group and their
values are not included in the statistical
analysis. Statistical analyses using Student's
t test were made to evaluate the differences
of the mean values obtained in the 4 groups
compared to Group 1 which had no meta-
stases.
For the purpose of comparison, an arbi-
trary limit to normal for the different para-
meters had to be established. The upper
limit of normal was arbitrarily set at one
s.d. above the mean value of the group
without metastasis. False negatives are those
of the bone metastasis group (Group 2), who
had a value below the upper limit of normal
(Group 1). False positive are those of
Group 1, who have a value above the arbitrary
limit of normal.
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RESULTS
Comparison of mean values
The mean values for age, serum
calcium, phosphorus and alkaline phos-
phatase activity in the 4 groups are
shown in Table I and the mean values for
urinary 24-h excretion of calcium and
hydroxyproline are shown in Table II.
The group with a doubtful bone scan was
significantly older than the group with-
out metastases, indicating the difficulty
in interpreting the scan in older indivi-
duals. The group with definite bone
metastases differed statistically from the
group without bone metastases in their
values for mean serum phosphorus and
alkaline phosphatase activity and urinary
calcium and hydroxyproline levels.
According to Student's t test, urinary
hydroxyproline/creatinine ratio and serum
alkaline phosphatase activity discrimi-
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nate best between patients with bone
metastases and those without bone or
with soft tissue metastases. Urinary cal-
cium and serum phosphorus levels, on the
other hand, are poor discriminators.
The body size correction for hydroxy-
proline did not improve the discriminatory
value ofhydroxyproline. Althoughnearly
all biochemical parameters in the group
with a doubtful scan were higher than in
the group without metastases, only the
urinary calcium/creatinine (Ca/cr) ratio
was significantly higher. The group with
softtissue metastases had, comparedtothe
group without metastases, a significantly
higher mean alkaline phosphatase level.
Calcium excretion tended to be lower and
hydroxyproline excretion to be higher.
Urinary calcium/creatinine ratio (Ca/cr)
The distribution of the urinary Ca/cr
in the 4 groups is shown in Fig. 1. The
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FIG. 1.-Distribution of individual urinary Ca/cr ratios in groups of patients with breast cancer
at entry into the study. A: patients who developed bone metastases x or soft tissue metastases
0 during follow-up period. B: patients with bone metastases under treatment at the time of
urinary collections. Horizontal lines: group means. Broken lines: ± s.d.
282
-
-
-
-
-
-16
° 14
x
a) C 12
C
co .)
10
a)
0.
._
°0 8
0-
C
2
-o 6
0 4
c
283 HYDROXYPROLINE EXCRETION IN BREAST CANCER
o 0
0 o
co~~~
go
.,. Ai:.
A
e-
x e S
X0 e
_
x
0
* -1
B
0o0
0
0
A
RX-Scan- RX+ Scan + RX-Scan +
Group 1 3
-98
8
-w
0
A
Soft tissue
metastases
4
Fie(. 2. Distribution of individual urinary hydro/cr ratios in groups ofpatients with breast cancer
at entry into the study. Symbols as in Fig. 1.
distribution shows a large overlap between
Groups 1 and 2. Fifty-seven per cent of
the patients in Group 2 had a value
lower than one s.d. above the mean of
Group 1. The patients in Group 2
who at the time ofurine collection received
prednisone or a cystostatic drug are
shown separately (B), in order to see
whether the treatment had an influence
on the parameter studied. There is no
difference betweentreated and non-treated
groups in Ca/cr excretion.
Urinary hydroxyproline/creatinine ratio
(Hypro/cr)
The distribution of the urinary
Hypro/cr ratio in the 4 groups is shown
in Fig. 2. Although there is a highly
significant higher mean Hypro/cr in
Group 2, an overlap between groups
exists. Twelve per cent of Group 2 had
a false negative result. Treatment in
Group 2 (B) had no influence on mean
Hypro/cr value. Eleven of the 14 patients
who on follow-up developed bone meta-
stases had a normal Hypro/cr ratio at the
20
initial observation. The 3 patients who
had an elevated Hypro/cr ratio were in
Group 3. A few months later definite
radiological lesions were seen, at the site
where the initial scan showed a doubtful
increased activity. The other patients who
developed skeletal metastases in Group 3,
had their bone lesion at a site other
than the one shown in the original scan.
Serum alkaline pho8phatase
The distribution of the alkaline phos-
phatase activity in the 4 groups is shown
in Fig. 3. Group 2 has a significantly
higher meanthanthe other groups. Seven
per cent ofthis group had a false negative
result. Ten of the 14 patients who
developed bone metastases during the
follow-up period had a normal alkaline
phosphatase value. The 4 with a raised
value were in Group 3, and 3 of them also
had a raised Hypro/cr ratio. Of the 13
patients in Group 4, 5 had an alkaline
phosphatase value more than one s.d.
above the mean of Group 1. This arbi-
trary limit of normal (75 iu/l) is muchF. GIELEN ET AL.
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FIG. 3.-Distribution of individual serum alkaline phosphatase activity in groups of patients with
breast cancer at entry into the study. Symbols as in Fig. 1.
lower than the upper limit of the range
40 to 120 usually accepted for our labora-
tory.
DISCUSSION
The results of this study of 181 conse-
cutive patients with breast carcinoma
confirm thosereportedbyothers (Rubegni,
Ravenni and Del Giovane, 1962; Platt et
at., 1964; Bonadonna et at., 1966; Hosley
et al., 1966; Guzzo et al., 1969; Cushieri
and Felgate, 1972; Summer et al., 1973),
that increased hydroxyproline excretion
is a sensitive index of the presence of
bone metastases.
Although raised levels of serum alka-
line phosphatase are strongly correlated
with bone metastases, the interpretation
in individual patients is difficult because
of the possibility of liver metastases.
Urinary hydroxyproline excretion is a
reliable method of selecting those patients
whose elevated serum alkaline phospha-
tase is secondary to bone disease, as
opposed to those resulting from liver
disease. Cerda et al. (1970) believe that
the measurement of urinary hydroxy-
proline has advantages over procedures
like electrophoresis, heat stability and
chemical inhibition in characterizing the
bone or liver source of an elevated serum
alkaline phosphatase. While metastatic
liver disease may cause elevations in the
serum alkaline phoSphatase, concomitant
elevations in the urinary hydroxyproline
are usually absent (Hosley et al., 1966).
Furthermore, estimation of hydroxy-
proline excretion gives information on the
activity of bone metastases which cannot
be given by radiological or scintigraphic
methods, which ate more static. Once
a bone metastasi8 is present, whether or
not it is very active, it will usually show
on radiographs or scintigrams. The low
Hypro/cr value in the radiological positive
groups indicates a low bone activity.
From our data, it is doubtful whether
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urinary hydroxyproline excretion will help
to detect bone metastases before they are
apparent on scintigrams. When a bone
scan is doubtful, as often occurs in older
subjects who may have spondylosis or
osteoporosis in addition, the estimation
ofhydroxyproline may be helpful. Three
out of 14 patients with a doubtful scan
developed radiologically visible lesions
later at the site where the bone scan was
doubtful. These 3 patients also had
elevated Hypro/cr and alkaline phos-
phatase, which indicate that they had
bone metastases at the time of urine
collection, despite the absence of radio-
logically visiblelesions. Whenscintigraphy
is not available, an elevation of hydroxy-
proline excretion may thus pre-date by
several months the radiological demon-
stration of osseous deposits, as has been
reportedbyGuzzo etal. (1969) and Cushieri
(1973). Since scintigraphy unfortunately
requires expensive equipment and is not
universally available, measurement of
hydroxyproline excretion is a cheaper
and simpler way to select these patients
with disseminated disease and to save
them from extensive radical treatment.
In addition to the value of hydroxy-
proline excretion in the initial investiga-
tions for bone deposits, it is useful in
monitoring the progression of metastatic
cancer of the breast. After new treat-
ment had been started, Powles, Leese and
Bondy (1975) observed that changes
in the hydroxyproline excretion occurred
ealier than other clinically observable
responses. The test could therefore be
used for predicting the response to
treatment and early detection of the
sensitivity of the tumour to hormone
therapy.
The final outcome for the patient
cannotbepredictedbythelevelofhydroxy-
proline excretion at the time of investiga-
tion, as Platt et al. (1964) suggested,
since the mean Hypro/cr ratio was only
slightly higher in those who died within
the 1P5-yr follow-up period than in
those who survived this period (7-22 vs
6-661: t = 0-595).
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